ClinicalTrials.gg
Not yet recruitingNCT07515677DDP-DMUpdated Apr 13, 2026

Digital Discharge Planning to Improve Self-Management in Patients With Diabetes Mellitus

An interventional study of Digital Discharge Planning Application and Standard Discharge Planning in Diabetes (DM), sponsored by Universitas Muhammadiyah Surakarta. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Universitas Muhammadiyah Surakarta · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Diabetes Mellitus with a site in Indonesia — 7 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus · Indonesia.

Planned enrollment
17th of 29
78 · median 84
Started
2026
with 4 others
No phase
18 of 46
3 open now
Registered
45th of 46
by date

Among the 46 studies in Diabetes Mellitus with a site in Indonesia, this one is the 17th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 with no phase, and was the 45th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

7 of the 46 studies in Diabetes Mellitus with a site in Indonesia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Diabetes Mellitus with a site in Indonesia, or all of them as a file.
02

Study summary

Diabetes mellitus is a chronic disease that requires continuous self-management to prevent complications and hospital readmissions. However, discharge planning in many hospitals is often delivered verbally and lacks structured follow-up after patients return home, which may lead to poor self-management behaviors.

This study aims to evaluate the effectiveness of a digital discharge planning intervention delivered through a mobile application to improve self-management among patients with diabetes mellitus after hospital discharge. The intervention is based on the Chronic Care Model and includes educational materials, reminders, and monitoring tools related to seven dimensions of diabetes self-management.

A randomized controlled trial with a parallel-group design will be conducted among patients with diabetes mellitus. Participants in the intervention group will receive digital discharge planning through a mobile application for 90 days after discharge, while the control group will receive standard discharge planning provided by the hospital. Primary outcomes include patient self-management behavior, while secondary outcomes include glycemic control and hospital readmission within 90 days.

Read the detailed description

Diabetes mellitus is one of the most prevalent chronic diseases worldwide and requires long-term self-management to maintain glycemic control and prevent complications. Effective discharge planning plays an important role in preparing patients to manage their condition independently after leaving the hospital. However, in many clinical settings, discharge planning is often delivered verbally and without structured follow-up, which may limit patients' ability to maintain appropriate self-management behaviors.

This study develops and evaluates a digital discharge planning model delivered through a mobile application to support patients with diabetes mellitus after hospital discharge. The intervention is theoretically grounded in the Chronic Care Model and supported by nursing theories including Orem's Self-Care Deficit Theory, Watson's Human Caring Theory, and Pender's Health Promotion Model.

The mobile application includes several features designed to support diabetes self-management based on the Diabetes Canada framework, including healthy eating, physical activity, blood glucose monitoring, medication adherence, problem solving, reducing risks, and healthy coping. The application provides educational materials, reminders, daily activity tracking, and feedback to encourage patient engagement and adherence to self-management practices.

A randomized controlled trial with a parallel-group design will be conducted to evaluate the effectiveness of the intervention. Participants will be randomly assigned to either the intervention group receiving digital discharge planning through the mobile application or the control group receiving standard discharge planning provided by the hospital. The intervention period will last for 90 days following hospital discharge. The study will assess the impact of the digital discharge planning model on self-management behaviors, glycemic control, and hospital readmission among patients with diabetes mellitus.

03

Conditions studied

  • Diabetes (DM)

Browse trials for

Keywords

  • Diabetes Self-Management
  • Digital Health Intervention
  • Discharge Planning
  • Mobile Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with diabetes mellitus.
  • Age 18 years or older.
  • Hospitalized patients who are preparing for discharge.
  • Able to use a smartphone and access the mobile application.
  • Willing to participate and provide .

Exclusion criteria

Exclusion Criteria:

  • Patients with severe complications requiring intensive care.
  • Patients with cognitive impairment or severe mental illness that may interfere with participation.
  • Patients who are unable to operate a smartphone or mobile application.
  • Patients who decline to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Digital Discharge Planning

    Participants receive digital discharge planning through a mobile application for 90 days after hospital discharge.

    Behavioral: Digital Discharge Planning Application

  • Active comparator
    Standard Discharge Planning

    Participants receive standard discharge planning routinely provided by the hospital.

    Behavioral: Standard Discharge Planning

Interventions

  • BehavioralDigital Discharge Planning Application

    A mobile health application designed to support diabetes self-management after hospital discharge, including education, reminders, and monitoring tools for 90 days.

  • BehavioralStandard Discharge Planning

    Participants receive standard discharge planning routinely provided by the hospital according to usual care procedures.

06

What researchers measure

Primary outcomes

  1. Change in diabetes self-management score

    Diabetes self-management will be assessed using an adapted Indonesian version of the Summary of Diabetes Self-Care Activities (SDSCA) questionnaire consisting of 21 items across seven domains (healthy eating, physical activity, blood glucose monitoring, medication adherence, problem solving, risk reduction, and healthy coping). Each item is scored on a 5-point Likert scale (1-5) reflecting frequency of behavior during the past 7 days. Total scores range from 21 to 105, with higher scores indicating better diabetes self-management behavior.

    Time frame: Baseline to 90 days after hospital discharge

Secondary outcomes

  1. Change in HbA1c level

    Glycemic control will be assessed by measuring glycated hemoglobin (HbA1c) levels before the intervention and at the end of the 90-day follow-up period.

    Time frame: Baseline to 90 days

  2. Hospital readmission within 90 days

    Hospital readmission due to diabetes-related complications within 90 days after discharge will be recorded from hospital records.

    Time frame: Within 90 days after hospital discharge

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to privacy and confidentiality considerations. Data may be available from the principal investigator upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 6 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07515677
Lead sponsor
Universitas Muhammadiyah Surakarta
Responsible party
Ririn Kartika Novitasari (Master's Student, Nursing Science Program, Universitas Muhammadiyah Surakarta) — Principal investigator
First posted
Apr 7, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Ririn Kartika Novitasari
Contact
j218240017@student.ums.ac.id
+6285728040905

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion